ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 4ÔÂ17ÈÕ£¬¸´ºêººÁعÙ΢Ðû²¼ÐÂÎųƣ¬Æä×ÔÖ÷¿ª·¢µÄÁ¢ÒìÐÍ¿¹TIGIT FcÈÚºÏÂѰ×HLX53ÁªºÏHÒ© ººË¹×´?£¨Ë¹Â³Àûµ¥¿¹£¬HLX10£©¼°ºº±´Ì©?£¨±´·¥Öéµ¥¿¹£¬HLX04£©µÄÐÂÒ©ÁÙ´²ÊÔÑéÉêÇë»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©Åú×¼£¬ÓÃÓÚ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔ¸Îϸ°û°©µÄÒ»ÏßÖÎÁÆ¡£
2. 4ÔÂ17ÈÕ£¬ÉîÐÅÉúÎïÐû²¼ÆäÔÚÑйãÆ×ÐÂÐ͹Ú×´²¡¶¾£¨COVID£©mRNAÒßÃçIN002.5.1»ñµÃÃÀ¹úʳÎïÒ©Æ·¼àÊÓÖÎÀí¾Ö(FDA) ¢òÆÚÁÙ´²ÊÔÑéÅú×¼¡£
3. 4ÔÂ17ÈÕ£¬CDE¹ÙÍø¹«Ê¾£¬Èüŵ·Æ£¨Sanofi£©1ÀàÐÂÒ©frexalimab×¢ÉäÒº»ñµÃÁ½ÏîÁÙ´²ÊÔÑéĬʾÔÊÐí£¬»®·ÖÄ⿪·¢ÖÎÁƳÉÈ˸´·¢ÐͶ෢ÐÔÓ²»¯£¨RMS£©¡¢³ÉÈ˷Ǹ´·¢ÐԼ̷¢Ï£ÍûÐͶ෢ÐÔÓ²»¯£¨nrSPMS£©¡£
4. 4ÔÂ16ÈÕ£¬¿µÕÜÒ©ÒµÐû²¼£¬ÆäÁ×Ëá«¿ÉÌæÄáÈé¸àÒѾÔÚÖйú°ÄÃŵØÇø»ñÅúÉÏÊУ¬ÓÃÓÚÖÎÁÆ12Ëê¼°ÒÔÉÏÇàÉÙÄêºÍ³ÉÈË»¼Õß°éÃæ²¿ÊÜÀ۵ķǽڶÎÐͰ×ñ°·ç¡£¹ûÕæ×ÊÁÏÏÔʾ£¬ÕâÊÇ¿µÕÜÒ©ÒµÓÚ2023Äê12ÔÂ×ÔIncyte¹«Ë¾Òý½øµÄÒ»¿î¾Ö²¿JAKÒÖÖÆ¼Á¡£
1. ¿ËÈÕ£¬ÉϺ£Ê«½¡ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾Óë°²»Õ°²¿ÆÉúÎ﹤³Ì£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾Ç©ÊðÊÚȨÏàÖúÐÒ顣ƾ֤¸ÃÊÚȨÐÒ飬ʫ½¡ÉúÎォÆäADCÊÖÒÕÆ½Ì¨EZWi-Fit?ÊÚȨ°²¿ÆÉúÎï¾ÙÐÐADC²úÆ·µÄ¿ª·¢¡£ÊÚȨʱ´ú£¬°²¿ÆÉúÎォÈÏÕæËùÑвúÆ·ÔÚ´óÖлªµØÇøµÄÁÙ´²Ç°Ñо¿¡¢ÁÙ´²¿ª·¢ºÍÉÌÒµ»¯Éú²úºÍÏúÊÛ£¬²¢ÏòÊ«½¡ÉúÎïÖ§¸¶È¨Ò渶¿î£¨°üÀ¨Ê׸¶¿îºÍÀï³Ì±®¿î£©¼°Õ¼¾»ÏúÊÛ¶îÒ»¶¨±ÈÀýµÄÏúÊÛÌá³É¡£Ê«½¡ÉúÎï»ñµÃ¸ÃADC²úÆ·µÄÍâÑóÈ¨Òæ¡£
1. 4ÔÂ17ÈÕ£¬±±¾©ÉúÃü¿ÆÑ§Ñо¿ËùÉÛ·å¼°±±¾©ÄÔ¿ÆÑ§ÓëÀàÄÔÑо¿ËùÂÞÃôÃôÅäºÏͨѶÔÚNature ÔÚÏß½ÒÏþÌâΪ¡°Brain endothelial GSDMD activation mediates inflammatory BBB breakdown¡±µÄÑо¿ÂÛÎÄ£¬¸ÃÑо¿°ûÖÊÖ¬¶àÌÇ(LPS)´«¸ÐÆ÷caspase-11¼¤»î³É¿×ÂѰ×GSDMD£¬µ«²»ÊÇͨ¹ýTLR4ÓÕµ¼µÄϸ°ûÒò×Ó£¬ÔÚÑ»·LPS»òLPSÓÕµ¼µÄ°ÜѪ֢Öн鵼ѪÄÔÆÁÕÏÆÊÎö¡£
[1]Wei, C., Jiang, W., Wang, R. et al. Brain endothelial GSDMD activation mediates inflammatory BBB breakdown. Nature (2024). https://doi.org/10.1038/s41586-024-07314-2